|
Characteristic
|
HT group (n = 59)
|
MCT group (n = 79)
|
P value
|
|---|
|
Age (years)a
| | |
0.009 (t test)
|
|
Median
|
49
|
50
| |
|
Range
|
37–76
|
34–66
| |
|
KPS score
| | |
0.349
|
|
90–100
|
46 (78.0)
|
56 (70.9)
| |
|
70–80
|
13 (22.0)
|
23 (29.1)
| |
|
Menopausal status
| | |
0.520
|
|
Premenopausal
|
20 (33.9)
|
31 (39.2)
| |
|
Postmenopausal
|
39 (66.1)
|
48 (60.8)
| |
|
HR status
| | | |
|
ER-positive
|
55 (93.2)
|
73 (92.4)
|
0.855
|
|
PgR-positive
|
51 (86.4)
|
65 (82.2)
|
0.509
|
|
Adjuvant HT
| | |
0.246
|
|
Yes
|
50 (84.7)
|
72 (91.1)
| |
|
No
|
9 (15.3)
|
7 (8.9)
| |
|
DFS (years)
| | |
0.446
|
|
<2
|
16 (27.1)
|
17 (21.5)
| |
|
≥2
|
43 (72.9)
|
62 (78.5)
| |
|
Mediana (months)
|
44
|
42
|
0.178 (t test)
|
|
No. of metastases
| | |
0.006
|
|
<2
|
30 (50.9)
|
22 (27.9)
| |
|
≥2
|
29 (49.1)
|
57 (72.1)
| |
|
Metastatic sites
| | |
0.168
|
|
Viscera
|
32 (54.2)
|
52 (65.8)
| |
|
Non-viscera
|
27 (45.8)
|
27 (34.2)
| |
|
Prior adjuvant CT
| | | |
|
Anthracycline
|
54 (91.5)
|
70 (88.6)
|
0.749
|
|
Taxanes
|
32 (54.2)
|
53 (67.1)
|
0.170
|
|
Response to FCCT
| | |
0.009
|
|
CR + PR
|
28 (47.4)
|
55 (69.6)
| |
|
SD
|
31 (52.3)
|
24 (30.4)
| |
-
HT hormonal therapy, MCT maintenance capecitabine monotherapy, KPS Karnofsky performance status, HR hormone receptor, ER estrogen receptor, PgR progesterone receptor, DFS disease-free survival, CT chemotherapy, FCCT first-line capecitabine-based combination chemotherapy, CR complete response, PR partial response, SD stable disease
-
aExcept for these values, others are presented as the numbers of patients followed by the percentages in the parentheses
